Revenue in the first half of 2024 reached € 2.79 billion (+8%; +10% CER1), net sales were € 2.64 billion (+11%; +13% CER1)
Strong net sales performance by newly launched growth drivers: BIMZELX® € 215 million, EVENITY® € 46 million, FINTEPLA® € 154 million, RYSTIGGO® € 77 million, ZILBRYSQ® € 15 million (since April’24)
Underlying profitability (adj. EBITDA2) was € 652 million (-19%; -13% CER1), 23% of revenue – driven by the strong investment behind the launches
5 regulatory approvals: EU: RYSTIGGO® for generalized myasthenia gravis (gMG), BIMZELX® as the first IL-17A and IL-17F biologic for hidradenitis suppurativa (HS); Japan: FINTEPLA® for Lennox-Gastaut syndrome (LGS) and BRIVIACT® for epilepsy; China: BIMZELX® for ankylosing spondylarthritis (AS)
Improved ESG ratings from ISS ESG and Sustainalytics, putting UCB into the top 10% of pharma and biotech companies globally
Financial guidance for 2024 confirmed: Revenue expected now at the top-end of € 5.5-5.7 billion, adjusted EBITDA2 23.0-24.5% of revenue, Core EPS3 of € 3.70-4.40
UCB Half-Year Report 2024, Brussels (Belgium), 25 July 2024 – 7:00 (CEST) – regulated information


"UCB’s Growth Path for a Decade Plus continues with strong launches around the globe allowing people with severe diseases to live the life they like, as free as possible from challenges of disease. The global number of patients using BIMZELX® has exceeded 35,000, supported by the strong launch in psoriasis in the U.S. since November 2023," Jean-Christophe Tellier, CEO UCB commented. "We are expecting to expand the offering of BIMZELX® to people living in the U.S. with spondyloarthritides indications and hidradenitis suppurativa at the end of this year. We will continue to execute the multiple launches around the globe, next to BIMZELX®, RYSTIGGO® and ZILBRYSQ® in generalized myasthenia gravis - driving company growth. We are pleased with the growing access to our medicines across our regions, and the further improved ESG ratings reflecting our efforts to create value for all stakeholders, now and into the future.”

see & read more on
https://www.ucb.com/stories-media/Press-Releases/article/Strong-Start-into-UCB-s-Decade-of-Growth